Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
BACKGROUND
The efficacy of statins, which are used commonly in primary and secondary prevention of cardiovascular diseases, shows a wide range of interindividual variability. Genetic variants of OATP1B1, a hepatic uptake transporter, can modify access of statins to its therapeutic target, thereby potentially altering drug efficacy. We studied the impact of genetic variants of OATP1B1 on the lipid-lowering efficacy of statins in a population-based setting.


METHODS
The basis of the analysis was the Study of Health in Pomerania, a cohort of 2732 men and women aged 20-81 years. Included in the statistical analysis to evaluate the impact of OATP1B1 on therapeutic efficacy of statins were 214 individuals diagnosed with dyslipidaemia during initial recruitment and receiving statins during the 5-year follow-up.


RESULTS
Analysing the impact of the OATP1B1 genotype, we observed a trend for lower statin-induced total cholesterol reduction in carriers of the SLCO1B1 512C variant. Restricting the analysis to patients receiving simvastatin, pravastatin, lovastatin and fluvastatin indicated a statistically significant association of the OATP1B1 genotype on lipid parameters at the 5-year follow-up. No such effect was observed for atorvastatin. Calculation of achievement of treatment goals according to the NCEP-ATPIII guidelines showed a lower rate of successful treatment when harbouring the mutant allele for patients taking simvastatin (46.7 vs. 73.9%). A similar trend was observed for pravastatin (34.4 vs. 70.4%).


CONCLUSIONS
Genetic variants of OATP1B1 leading to impaired hepatic uptake of statins translated into reduced drug efficacy in a population-based cohort.
aBiopharmacy Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland bInstitute of Pharmacology cInstitute of Community Medicine dInstitute of Clinical Chemistry and Laboratory Medicine, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany.
Henriette E
HE
Meyer zu Schwabedissen
Martin
M
Albers
Sebastian E
SE
Baumeister
Christian
C
Rimmbach
Matthias
M
Nauck
Henri
H
Wallaschofski
Werner
W
Siegmund
Henry
H
Völzke
Heyo K
HK
Kroemer
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D054316:Biomarkers, Pharmacological; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage; D005260:Female; D000077340:Fluvastatin; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage; D050356:Lipid Metabolism / Q000187:drug effects / Q000235:genetics*; D027381:Liver-Specific Organic Anion Transporter 1; D008148:Lovastatin / Q000008:administration & dosage / Q000235:genetics; D008297:Male; D008875:Middle Aged; D027361:Organic Anion Transporters / Q000235:genetics*; D017035:Pravastatin / Q000008:administration & dosage / Q000235:genetics; D018570:Risk Assessment; D019821:Simvastatin / Q000008:administration & dosage
D054316:Biomarkers, Pharmacological; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human; D000077340:Fluvastatin; D008148:Lovastatin; D019821:Simvastatin; D017035:Pravastatin